Cancer Immunotherapy Guidelines Cutaneous Melanoma

The Society for Immunotherapy of Cancer (SITC) developed and published the first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with cutaneous melanoma in Nature Reviews Clinical Oncology in 2013.

On Wednesday, May 30, 2018, SITC published an update in the Journal for ImmunoTherapy of Cancer (JITC), the society's open access, peer-reviewed online journal.

This updated consensus statement provides expert evidence-based recommendations for the use of immunotherapies including checkpoint inhibitor monotherapies and combinations, as well as oncolytic viruses, interferon-α2, and interleukin-2 in various disease stages and settings. This statement also includes recommendations for patient selection, sequencing or combination of therapies, using and screening for predictive biomarkers, managing adverse events, and selecting optimal clinical endpoints.

Current Guideline

Up-To-Date

Published May 30, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 ."

Cancer Immunotherapy Guidelines Cutaneous Melanoma

subcommittee leadership

Howard L. Kaufman, MD, FACS
Committee Chair – Replimune Group Inc.

Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Care Center

F. Stephen Hodi, Jr., MD
Dana-Farber Cancer Institute

John M. Kirkwood, MD
University of Pittsburgh

subcommittee members

Sanjiv Agarwala, MD St. Luke´s Cancer Center and Temple University	Joseph I. Clark, MD Loyola University Medical Center
Marc S. Ernstoff, MD Roswell Park Cancer Institute	Leslie A. Fecher, MD University of Michigan
Thomas F. Gajewski, MD, PhD University of Chicago	Brian Gastman, MD Cleveland Clinic
David H. Lawson, MD Winship Cancer Institute of Emory University	Jose Lutzky, MD, FACP Mount Sinai Medical Center
Kim A. Margolin, MD City of Hope	David F. McDermott, MD Beth Israel Deaconess Medical Center
Janice M. Mehnert, MD Rutgers Cancer Institute of New Jersey	Anna C. Pavlick, DO, MD New York University Cancer Institute
Jon M. Richards, MD, PhD Lutheran General Hospital	Krista M. Rubin, MS, FNP-BC Massachusetts General Hospital
William H. Sharfman, MD Johns Hopkins Oncology Center	Steven Silverstein, MBA Melanoma Research Foundation
Craig L. Slingluff, MD University of Virginia	Vernon K. Sondak, MD H. Lee Moffitt Cancer Center & Research Institute
Ryan J. Sullivan, MD Massachusetts General Hospital	Ahmad A. Tarhini, MD, PhD Cleveland Clinic Taussig Cancer Institute
*John A. Thompson, MD* Seattle Cancer Care Alliance	Walter J. Urba, MD, PhD Earle A. Chiles Research Institute, Providence Cancer Center
Richard L. White, Jr., MD, FACS Carolinas Medical Center	Eric D. Whitman, MD, FACS Atlantic Health System Cancer Care

Pocket Guides

Key points from SITC's Cancer Immunotherapy Guidelines have been distilled into Pocket Guides. These condensed, easily accessible versions of the full Cancer Immunotherapy Guidelines are a quick-reference tool available in both digital and print.

Download SITC's Cancer Immunotherapy Pocket Guides on any desktop or mobile device free today.*

*Available only through the Guideline Central App.

ORDER Digital/Print Guides

Cancer Immunotherapy Guidelines Cutaneous Melanoma

Current Guideline

Up-To-Date

Cancer Immunotherapy Guidelines Cutaneous Melanoma

subcommittee leadership

subcommittee members

Pocket Guides

Membership Links

Get Involved